Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07117825
Active, not recruiting Observational

Aortic Dissection fAlse enlarGement radIomics predictiOn

NCT07117825 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Started
2024-09-30
Last updated
2025-08-12

Condition(s) studied

DissectionAortic DiseasesAortic Dissection

Investigational drug(s) / intervention(s)

AORTIC DISSECTION CT SCAN ANALYSIS

AORTIC DISSECTION CT SCAN ANALYSIS: Patients with type A or type B acute aortic dissection, treated either with medical therapy or with endovascular/open surgery in the study period and who underwent subsequent radiological follow-up.

Study summary

The objective of this study is to find, in acute phase of aortic dissection, CT scans characteristics through radiomics features, that can help us to predict a significant growth of dissected descending aorta or a false lumen enlargement in order to treat the patient promptly.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with previous acute aortic (type A or B) dissection, undergoing medical or surgical therapy and in clinical-radiological follow-up. Exclusion Criteria: * Patients with no appropriate radiological follow up; * Patients who died in the acute phase of aortic type A or B dissection.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Giovanni Tinelli Roma Italy

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

Ultrasound Monitoring of Muscle Thickness in Premature Patients Active, not recruiting
GCP-R3 Clinical Practice Survey in Research Centers Recruiting
Intracoronary Provocative Test With Acetylcholine in Patients With INOCA and MINOCA Recruiting
FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae Recruiting
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations. Recruiting

Other trials for the same condition

Use of Shockwave M5+/L6 IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access Recruiting
Mid- and Long-term Outcomes of Custom-made Aortic Devices Recruiting
International Multicenter Mycotic Aneurysm Aorto-iliac Study Recruiting
Valved Graft PMCF Study Recruiting
Thoraflex Hybrid Post-Market Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07117825 on ClinicalTrials.gov ↗ ← All trials in Italy